Coya Therapeutics Reports 49% Increase in Collaboration Revenue for Q2 2026

Coya Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a collaboration revenue of $243,745, a 49% increase from $163,616 in the same period last year. For the first half of 2026, collaboration revenue reached $494,892, compared to $421,500 in the first half of 2025. Despite this growth in revenue, the company continues to face significant operating losses, with a net loss of $6.6 million for the quarter, slightly higher than the $6.1 million loss reported in the same quarter of 2025. For the six months ending June 30, 2026, the net loss was $13.8 million, compared to $13.4 million for the same period in 2025.

Operating expenses for Coya increased to $7.3 million in the second quarter of 2026, up from $6.6 million in the prior year, primarily driven by a $1.4 million rise in research and development expenses, which totaled $5.0 million for the quarter. This increase reflects the company's ongoing investment in its clinical programs, particularly the advancement of COYA 302, a treatment for amyotrophic lateral sclerosis (ALS). General and administrative expenses decreased to $2.3 million from $2.9 million, attributed to reduced professional services and employee compensation costs.

Coya's operational developments include the ongoing ALSTARS Trial, a Phase 2 study evaluating COYA 302 for ALS, which has received Fast Track Designation from the FDA. The company continues to focus on enhancing its pipeline, which includes proprietary therapies aimed at improving regulatory T cell function to address neurodegenerative and autoimmune diseases. As of June 30, 2026, Coya had cash and cash equivalents of $43.2 million, which it expects will fund operations into the second half of 2027.

The company has also entered into a Sales Agreement with Leerink Partners LLC, allowing it to sell up to $30 million in common stock through an at-the-market offering program. This move is part of Coya's strategy to secure additional funding necessary for its ongoing research and development efforts. However, the company acknowledges the need for substantial additional financing to support its operations and product development, as it has not yet commercialized any products and does not anticipate generating revenue from product sales in the near future.

Looking ahead, Coya Therapeutics anticipates continued significant expenses and operating losses as it advances its product candidates through clinical trials and seeks regulatory approval. The company remains focused on its strategic goals while navigating the challenges of funding and market conditions that could impact its growth trajectory.